Treatment of candiduria with micafungin: A case series

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 18, Issue 2, 2007, Pages 149-150

  Lagrotteria, Danny ^a   Rotstein, Coleman ^a   Lee, Christine H ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Candiduria; Echinocandins

Indexed keywords

ANTIFUNGAL AGENT; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRROLE; TACROLIMUS;

ADULT; AGED; ANAMNESIS; ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; CASE REPORT; CELLULITIS; CLINICAL FEATURE; CYSTITIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DYSURIA; FEMALE; HOSPITAL INFECTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; MALE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; PELVIC DISEASE; PYODERMA GANGRENOSUM; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINARY URGENCY;

EID: 34250352640     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/768734     Document Type: Article

References (12)

1. Kauffman CA, Vazquez JA, Sobel JD. Prospective multicenter surveillance study of fungutia in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000;30:14-8.
2. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP; National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30.
3. Fidel PL, Vazquez J A, Sobel JD. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999;12:80-96.
4. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247-51.
5. Rivett AG, Perry JA, Cohen J. Urinary candidiasis: A prospective study in hospitalized patients. Urol Res 1986;14:183-6.
6. Hithcock CA, Pye GW, Troke PF, Johnson EM, Warnock DW. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 1993;37:1962-5.
7. Baran J Jr, Klauber E, Barczak J, Riederer K, Khatib R. Trends in antifungal susceptibility among Candida sp. urinary isolates from 1994 and 1998. J Clin Microbiol 2000;38:870-1.
8. Harris AD, Castro J, Sheppard DC, Carmeli Y, Samore MH. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans. Clin Infect Dis 1999;29:926-8.
9. Kurtz MB, Abruzzo G, Flattery A, et al. Characterization of echinocandin-resistant mutants of Candida albicans: Genetic, biochemical, and virulence studies. Infect Immun 1996;64:3244-51.
10. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72.
11. Maki K, Morishita Y, Iguchi Y, et al. In vitro antifungal activity of FK463, a novel water-soluble echinocandin-like lipopeptide. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998 (Abstract F-141).
12. Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000;44:614-8.